

6. Literatur

ADLI M, BSCHOR T, CANATA B, DÖPFMER S, BAUER M: Lithium in der Behandlung der akuten Depression. *Fortschr Neurol Psychiat* 1998; 66: 435-441

ALVAREZ E, UDINA C, QUERALTO JM, ORDONEZ J, RODRIGUEZ J, CASAS M: Factors indicating the favourable response of lithium added to the treatment of resistant depressions. *Abstracts of the 14th Collegium Internationale Neuro-Psychopharmacologicum Congress. Florence, Italy, 1984*

ALVAREZ E, PEREZ-SOLA V, PEREZ-BLANCO J, QUERALTO JM, TORRUBIA R, NOGUERA R: Predicting outcome of lithium added to antidepressants in resistant depression. *Journal of Affective Disorders* 1997; 42: 179-186

AMSTERDAM JD, MAISLIN G, WINOKUR A, KLING M, GOLD P: Pituitary and adrenocortical responses to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers. *Archives of General Psychiatry* 1987; 44: 775-781

AMSTERDAM JD, ROSENZWEIG M, MOZLEY PD: Assessment of adrenocortical activity in refractory depression: Steroid suppression with ketokonazole. In: NOLEN WA, ZOHAR J, ROOSE SP, AMSTERDAM JD (eds): *Refractory depression: Current strategies and future directions. John Wiley & Sons, 1994*

ARANA GW, BALDESSARINI RJ, ORNSTEEN M: The dexamethasone suppression test for diagnosis and prognosis in psychiatry. *Arch Gen Psychiatry* 1985; 42: 1193-1204

ARANA GW, SANTOS AB, LARAIA MT, McLEOD-BRYANT S, BEALE MD, RAMES LJ, ROBERTS JM, DIAS JK, MOLLOY M: Dexamethasone for the treatment of depression: A randomized, placebo-controlled, double-blind trial. *Am J Psychiat* 1995; 152: 265-267

BAASTRUP PC, POULSEN JC, SCHOU M, THOMSON K, AMDISEN A: Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. *Lancet* 1970; 2(7668): 326-330

BARDEN N, REUL JM, HOLSBOER F: Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? *Trends Neurosci* 1995; 18: 6-11

BAUER M: The combined use of lithium and SSRIs. *J Serotonin Res* 1995; 2: 69-76

BAUER M: Behandlung der akuten Depression mit Lithium. In: MÜLLER-OERLINGHAUSEN B, GREIL W, BERGHÖFER A: Die Lithiumtherapie. *Springer* 1997; 178-189

BAUER M, DÖPFMER S: Lithium augmentation in treatment-resistant depression: A meta-analysis of placebo-controlled studies. *J Clin Psychopharmacology* 1999; 19: 427-434

BAUER M, BSCHOR T, KUNZ D, BERGHÖFER A, STRÖHLE A, MÜLLER-OERLINGHAUSEN B: Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am J Psychiatry* 2000; 157: 1429-1435

BAUER M, WHYBROW PC, ANGST J, VERSIANI M, MÖLLER HJ: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. *World J Biol Psychiatr* 2002a; 3: 5-43

BAUER M, WHYBROW PC, ANGST J, VERSIANI M, MÖLLER HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive

disorder and treatment of chronic depressive disorders and subthreshold depressions. *World J Biol Psychiatr* 2002b; 3: 69-86

BAUER M, ADLI M, BSCHOR T, HEINZ A, RASGON N, FRYE M, GRUNZE H, KUPKA R, WHYBROW PC: Clinical applications of levothyroxine in refractory mood disorders. *Clinical Approaches in Bipolar Disorders* 2003a; 2: 49-56

BAUER M, FORSTHOFF A, BAETHGE C, ADLI M, BERGHÖFER A, DÖPFMER S, BSCHOR T: Lithium augmentation therapy in refractory depression – Update 2002. *Eur Arch Psychiatry Clin Neurosci* 2003b; 253: 132-139

BAUER M, ADLI M, BAETHGE C, BERGHÖFER A, SASSE J, BSCHOR T: Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. *Can J Psychiat* 2003c ; 48: 440-446

BAUMANN P, NIL R, SOUCHE A, MONTALDI S, BAETTIG D, LAMBERT S, UEHLINGER C, KASAS A, AMEY M, JONZIER-PEREY M: A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. *J Clin Psychopharmacol* 1996; 16: 307-314

BLIER P, DE MONTIGNY C, CHAPUT Y : Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. *J Clin Psychopharmacology* 1987; 7: 24-35

BOSTWICK JM, PANKRATZ VS: Affective disorders and suicide risk: A reexamination. *Am J Psychiatry* 2000; 157: 1925-1932

BRODERICK P, LYNCH V: Behavioral and biochemical changes induced by lithium and L-tryptophan in murine rats. *Neuropharmacology* 1982; 21: 671-679

BSCHOR T, BAUER M: Schilddrüsenfunktion bei Lithiumbehandlung. *Nervenarzt* 1998; 69:189-195

BSCHOR T, CANATA B, MÜLLER-OERLINGHAUSEN B, BAUER M: Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. *J Affect Disorders* 2001; 64: 261-265

BSCHOR T, BERGHÖFER A, STRÖHLE A, KUNZ D, ADLI M, MÜLLER-OERLINGHAUSEN B, BAUER M: How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. *J Clin Psychopharmacology* 2002; 22: 427-430

BSCHOR T, BAUER M: Therapieresistente Depressionen. In: HOHAGEN F, LINDEN M, NABER D (Hrsg.): Referenzreihe Psychiatrie und Psychotherapie, Band Nr. VI Affektive Störungen. *Thieme Verlag, Stuttgart* (im Druck)

BSCHOR T, BAUER M: Is successful lithium augmentation limited to serotonergic antidepressants? *J Clin Psychopharmacol* 2004; (im Druck)

CADE JFJ: Lithium salts in the treatment of psychotic-excitement. *Med J Aust* 1949; 36: 349-352

CARROLL BJ, FEINBERG M, GREDEN JF, TARIKA J, ALBALA AA, HASKETT RF, JAMES NM, KRONFOL Z, LOHR N, STEINER M, DE VIGNE JP, YOUNG E: A specific laboratory test for the diagnosis of melancholia. *Arch Gen Psychiatry* 1981; 38: 15-22

COPPEN A: The biochemistry of affective disorders. *Br J Psychiatry* 1967; 113: 1237-1264

COURNOYER G, DE MONTIGNY C, OUELLETTE J, LEBLANC G, LANGLOIS R, ELIE R: Lithium addition in tricyclic-resistant unipolar depression: a placebo-

controlled study. *Abstracts of Collegium Internationale Neuropsychopharmacologicum*, Florence, Italy, June 19-23, 1984, p.179

DE MONTIGNY C, AGHAJANIAN GK: Tricyclic antidepressants: long-term treatment increases responsiveness of rat forebrain neurons to serotonin. *Science* 1978; 202: 1303-1306

DE MONTIGNY C, GRUNBERG F, MAYER A, DESCHENES JP: Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. *Br J Psychiatry* 1981; 138: 252-256

DE MONTIGNY C, COURNOYER G, MORISSETTE R, LANGLOIS R, CAILLE G: Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. *Arch Gen Psychiatry* 1983; 40: 1327-1334

DE MONTIGNY C: Lithium addition in refractory depression. In: NOLEN WA, ZOHAR J, ROOSE SP, AMSTERDAM JD (eds): *Refractory depression: current strategies and future directions*. London: John Wiley & Sons Ltd, 1994, 47-57

DILLING H, REIMER C, AROLT V: *Basiswissen Psychiatrie und Psychotherapie*. Springer, Berlin 2001; 116-125

DINAN TG: Glucocorticoids in the genesis of depression: a psychobiological perspective. *Br J Psychiatry* 1994; 164: 365-371

FELBER W: Die Lithiumprophylaxe der Depression vor 100 Jahren – ein genialer Irrtum. *Fortschr Neurol Psychiatr* 1987; 55: 141-144

FELBER W: Suizide und Parasuizide bei Lithiumpatienten in der lithiumwirksamen und lithiumunwirksamen Zeit. In: WOLFERSDORF M, FELBER W (Hrsg.): *Suizidologie*. S. Roderer, Regensburg 1995; 205-214

FELBER W: Mortalitätsbefunde von Patienten mit affektiven Störungen unter Lithiumbehandlung. In: MARNEROS A, BRIEGER P (Hrsg.): Psychiatrie als Therapiefach. S. Roderer, Regensburg 1997; 147-152

GOLD PW, CHROUSOS G, KELLNER C, POST R, ROY A, AUGERINOS P, SCHULTE H, OLDFIELD E, LORIAUX DL: Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. *Am J Psychiatry* 1984; 141: 619-627

GOLD PW, LORIAUX DL, ROY A ET AL: Response to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease: Pathophysiologic and diagnostic implications. *N Engl J Med* 1986; 314: 1329-1335

GOODWIN FK, FIREMAN B, SIMON GE, HUNKELER EM, LEE J, REVICKI D: Suicide risk in bipolar disorder during treatment with lithium and divalproex. *JAMA* 2003; 290: 1467-1473.

HALBREICH U, ASNIS GM, SHINDLEDECKER R, ZUMOFF B, NATHAN RS: Cortisol secretion in endogenous depression. *Archives of General Psychiatry* 1985; 42: 904-908

HAMILTON M: A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23: 56-62

HEINZ A: Experimentelle Behandlungsansätze und Zukunftsperspektiven bei therapieresistenten Depressionen. In: BAUER M, BERGHÖFER A: Therapieresistente Depressionen. *Springer* 1997; 152-169

HEIT S, NEMEROFF CB: Lithium augmentation of antidepressants in treatment-refractory depression. *J Clin Psychiatry* 1998; 59 (suppl 6): 28-33

HENINGER GR, CHARNEY DS, STERNBERG DE: Lithium carbonate augmentation of antidepressant treatment. *Arch Gen Psychiatry* 1983; 40: 1335-1342

HEUSER I, YASSOURIDIS A, HOLSBOER F: The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. *J Psychiatr Res* 1994; 28: 341-356

HEUSER IJE, SCHWEIGER U, GOTTHARDT U, SCHMIDER J, LAMMERS CH, DETTLING M, YASSOURIDIS A, HOLSBOER F: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. *Am J Psychiatry* 1996; 153: 93-99

HEUSER I: The hypothalamic-pituitary-adrenal system in depression. *Pharmacopsychiat* 1998; 31: 10-13

HOLSBOER F, LIEBL R, HOFSCHUSTER E: Repeated dexamethasone suppression test during depressive illness: normalization of test results compared with clinical improvement: *J Affect Disord* 1982; 4: 93-101

HOLSBOER F: Prediction of clinical course by dexamethasone suppression test (DST) response in depressed patients - physiological and clinical construct validity of the DST. *Pharmacopsychiatria* 1983; 16: 186-191

HOLSBOER F, VON BARDELEBEN U, GERKEN A ET AL: Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor (hCRF) in depression. *N Engl J Med* 1984; 311: 1127-1137

HOLSBOER F, GERKEN A, VON BARDELEBEN U, GRIMM W, BEYER H, MÜLLER OA, STALLA GK: Human corticotropin-releasing hormone in depression – correlation with thyrotropin secretion following thyrotropin-releasing hormone. *Biol Psychiatry* 1986; 21: 601-611

HOLSBOER F, VON BARDELEBEN U, WIEDEMANN K, MÜLLER OA, STALLA GK: Serial assessment of corticotropin-releasing hormone response after dexamethasone

in depression: implications for pathophysiology of DST nonsuppression. *Biol Psychiatry* 1987a; 22: 228-234

HOLSBOER F, GERKEN A, STALLA GK, MÜLLER OA: Blunted aldosterone and ACTH release after human CRH administration in depressed patients. *Am J Psychiatry* 1987b; 144: 229-231

HOLSBOER F: Neuroendocrinology of mood disorders. In: BLOOM FE, KUPFER DJ (eds): *Psychopharmacology: The fourth generation of progress*. New York: Raven Press, 1995, 957-969

HOLSBOER F, LAUER CH J, SCHREIBER W, KRIEG JC: Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. *Neuroendocrinology* 1995; 62: 340-347

HOLSBOER F, BARDEN N: Antidepressants and HPA regulation. *Endocrinol Rev* 1996; 17: 187-203

HOLSBOER F: The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology* 2000; 23: 477-501

HOLSBOER-TRACHSLER E, STOHLER R, HATZINGER M: Repeated administration of the combined dexamethasone/hCRH stimulation test during treatment of depression. *Psychiatry Res* 1991; 38: 163-171

HOLSBOER-TRACHSLER E, HEMMETER U, HATZINGER M, SEIFRITZ E, GERHARD U, HOBI V: Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment – neurobiological and psychometric assessment of course. *J Psychiat Res* 1994; 28: 381-399

JACOBS JJ : Effect of lithium chloride on adrenocortical function in the rat. *Proc. Soc. Exp. Biol. Med.* 1978 ; 157: 163-167

JOFFE RT, LEVITT AJ, BAGBY RM, MACDONALD C, SINGER W: Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. *British Journal of Psychiatry* 1993a; 163: 574-578

JOFFE RT, SINGER W, LEVITT AJ, MACDONALD D: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. *Arch Gen Psychiatry* 1993b; 50: 387-393

JOYCE PR: Mood response to methylphenidate and the dexamethasone suppression test as predictors of treatment response to zimelidine and lithium in major depression. *Biol Psychiatry* 1985; 20: 598-604

KANTOR D, MCNEVIN S, LEICHNER P, HARPER D, KRENN M: The benefit of lithium carbonate adjunct in refractory depression - fact of fiction? *Can J Psychiatry* 1986; 31: 416-418

KAROW T, LANG R: Allgemeine und Spezielle Pharmakologie. *Eigenverlag*, Köln 2002; 379-380

KATONA CLE: Lithium augmentation in refractory depression. *Psychiatr Dev* 1988; 2: 153-171

KATONA CLE, FINCH EJM: Lithium augmentation for refractory depression in old age. In: AMSTERDAM JD (ed): *Advances in Neuropsychiatry and Psychopharmacology*, Vol 2: Refractory depression. *Raven Press*, New York, 1991; 177-184

KATONA CLE, ABOU-SALEH MT, HARRISON DA, NAIRAC BA, EDWARDS DRL, LOCK T, BURNS RA, ROBERTSON MM: Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. *Br J Psychiatry* 1995; 166: 80-86

KATONA CLE: Refractory depression: a review with particular reference to the use of lithium augmentation. *Eur Neuropsychopharmacology* 1995; 5 (suppl): 109-113

KLEIN DF, DAVIS JM: Diagnosis and drug treatment in psychiatric disorders. *Williams and Wilkins*, Baltimore 1979

KUSHMIR SL: Lithium-antidepressant combination in the treatment of depressed physically ill geriatric patients. *Am. J. Psychiat.* 1986; 143: 378-379

LANGÉ C: Om periodiske Depressionstilstande og deres Patogenese. *Jacob Lunds Forlag* 1886, Kjøbenhavn.

LAUER CJ, SCHREIBER W, MODELL S, HOLSBOER F, KRIEG JC: Die Münchner Vulnerabilitäts-Studie zu affektiven Erkrankungen. *Der Nervenarzt* 1998; 69: 574-585

LENOX RH, McNAMARA RK, PAPKE RL, MANIJK HK: neurobiology of lithium: an update. *J Clin Psychiatry* 2000; 61: 5-15

LESCH KP, LAUX G, SCHULTE HM, PFÜLLER H, BECKMANN H: Corticotropin and cortisol response to human CRH as a probe for HPA system integrity in major depressive disorder. *Psychiatry Research* 1988; 24: 25-34

LINDEN M, HELMCHEN H, MACKERT A, MÜLLER-OERLINGHAUSEN B: Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed inpatients. *Pharmacopsychiatry* 1994; 27(suppl.): 51-53

LINKOWSKI P, MENDLEWICZ J, KERKHOFS M, LECLERCQ R, GOLSTEIN J, BRASSEUR M, COPINSCHI G, VAN CAUTER E: Twenty-four hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: Effect of antidepressant treatment. *Journal of Clinical Endocrinology and Metabolism* 1987; 65: 141-152

MODELL S, YASSOURIDIS A, HUBER J, HOLSBOER F: Corticosteroid receptor function is decreased in depressed patients. *Neuroendocrinology* 1997; 65: 216-222

MÖLLER HJ, FISCHER G, VON ZERSSEN D: Prediction of therapeutic response in acute treatment with antidepressants. *Eur Arch Psychiatr Neurol Sci* 1987; 236: 349-357

MÖLLER HJ, LAUX G, DEISTER A: Psychiatrie. Duale Reihe, Hippokrates Verlag, Stuttgart 2001; 73-106

MÜLLER-OERLINGHAUSEN B, WOLF T, AHRENS B, SCHOU M, GROF E, GROF P, LENZ G, SIMHANDL C, THAU K, WOLF R: Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. *Acta Psychiatr Scand* 1994; 90: 295-297

MÜLLER-OERLINGHAUSEN B, BERGHÖFER A : Antidepressant and suicidal risk. *J Clin Psychiatry* 1999; 60 (suppl. 2): 94-99

NELSON JC, MAZURE CM: Lithium augmentation in psychotic depression refractory to combined drug treatment. *American Journal of Psychiatry* 1986; 143: 363-366

NELSON JC: Overcoming treatment resistance in depression. *J Clin Psychiatry* 1998; 59 (suppl. 16): 13-19

NEMEROFF CB, KRISHNAN KR, REED D ET AL.: Adrenal gland enlargement in major depression. *Archives of General Psychiatry* 1992; 49: 384-387

NEMEROFF CB: Augmentation strategies in patients with refractory depression. *Depress Anxiety* 1997; 4: 169-181

NIERENBERG AA, AMSTERDAM JD: Treatment-resistant depression: Definition and treatment approaches. *J Clin Psychiatry* 1990; 51 (suppl 6): 39-47

NIERENBERG AA, PAPAKOSTAS GI, PETERSON T, MONTOYA HD, WORTHINGTON JJ, TEDLOW J, ALPERT JE, FAVA M: Lithium augmentation of nortrip-

tyline for subjects resistant to multiple antidepressants. *Psychopharmacology* 2003; 23: 92-95

PEREZ-CRUET J, TAGLIAMONTE A, TAGLIAMONTE P, GESSA GL: Stimulation of serotonin synthesis by lithium. *J Pharmacol Exp Ther* 1971; 178: 325-330

PRICE LH, CHARNEY DS, HENINGER GR: Variability of response to lithium augmentation in refractory depression. *American Journal of Psychiatry* 1986; 143: 1387-1392

PRICE LH, CARPENTER LL, RASMUSSEN SA: Drug combination strategies. In: AMSTERDAM JD, HORNIG M, NIERENBERG AA (EDS.): Treatment-resistant mood disorders. Cambridge, University Press 2001, pp.194-222

PURBA JS, HOOGENDIJK WJG, HOFMAN MA, SWAAB DF: Increased number of vasopressin and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. *Arch Gen Psychiatry* 1996; 53: 137-143

REISINE T, ZATZ M: Interactions among lithium, calcium, diacylglycerides, and phorbol esters in the regulation of adrenocorticotropin hormone release from AtT-20 cells. *J Neurochem* 1987; 49: 884-889

REUL JMHM, STEC I, SÖDER M, HOLSBER F: Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. *Endocrinology* 1993; 133: 312-320

REUL JMHM, LABEUR MS, GRIGORIADIS DE, DE SOUZA EB, HOLSBORER F: Hypothalamic-pituitary-adrenocortical axis change in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. *Neuroendocrinology* 1994; 60: 509-519

RISCH SC, GOLSHAN S, RAPAPORT MH, DUPONT R, OUTENREATH R, GILLIN JC, JANOWSKY DS: Neuroendocrine effects of intravenous ovine corticotropin-

releasing factor in affective disorder patients and normal controls. *Biological Psychiatry* 1988; 23: 755-758

ROUILLON F, GORWOOD P: The use of lithium to augment antidepressant medication. *J Clin Psychiatry* 1998; 59 (suppl. 5): 32-39

RUBIN RT, PHILLIPS JJ, SADOW TF, MACCRACKEN JT: Adrenal gland volume in major depression: increased during the depressive episode and decreased with successful treatment. *Arch Gen Psychiatry* 1995; 52: 213-218

RUPPRECHT R, LESCH KP, MÜLLER U, BED G, BECKMANN H, SCHULTE HM: Blunted adrenocorticotropin but normal β -endorphin release after human corticotropin-releasing hormone administration in depression. *Journal of Clinical Endocrinology and Metabolism* 1989; 69: 600-603

RYBAKOWSKI JK, MATKOWSKI K: Lithium potentiation of various antidepressants. *1st Int. Conf. Refractory Depression*, Philadelphia, PA, October 6-7, 1988

RYBAKOWSKI JK, MATKOWSKI K: Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. *Eur Neuropsychopharmacol* 1992; 2: 161-165

RYBAKOWSKI JK, TWARDOWSKA K: The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. *Journal of Psychiatric Research* 1999; 33: 363-370

SCHÖPF J, BAUMANN P, LEMARCHAND T, REY M: Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. *Pharmacopsychiatry* 1989; 22: 183-187

SCHOU M: Normothymotics, "mood stabilizers": are lithium and imipramine drugs specific for affective disorders? *Brit J Psychiatry* 1963; 109: 803-809

SHELTON RC: Treatment options for refractory depression. *J Clin Psychiatry* 1999; 60 (suppl. 4): 57-61

STECKLER T, HOLSBOER F, REUL JMHM: Glucocorticoids and depression. *Baillière's Clin Endocrinol Metab* 1999; 13: 597-614

STEIN G, BERNADT M: Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. *Br J Psychiatry* 1993; 162: 634-640

STERNBACH H: The serotonin syndrome. *American Journal of Psychiatry* 1991; 148: 705-713

STOKES PE, PICK GR, STOLL PM, NUNN WD: Pituitary-adrenal function in depressed patients: Resistance to dexamethasone suppression. *J Psychiat Res* 1975; 12: 271-281

STOKES PE, STOLL PM, KOSLOW SH, MAAS JW, DAVIS JM, SWANN AC, ROBINS E: Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study. *Arch Gen Psychiatry* 1984; 41: 257-267

SUGAWARA M, HASHIMOTO K, HATTORI T, TAKAO T, SUEMARU S, OTA Z: Effects of lithium on the hypothalamo-pituitary-adrenal axis. *Endocrinol Japon* 1988; 35: 655-663

SWANN AC, HENINGER GR, ROTH RH, MAAS JW: Differential effects of short- and long-term lithium on tryptophan uptake and serotonergic function in cat brain. *Life Sci* 1981; 28: 347-354

THASE ME, RUSH AJ: Treatment-resistant depression. In: BLOOM FE, KUPFER DJ (eds.): *Psychopharmacology: The fourth generation of progress*. Raven Press, New York, 1995, 1081-1097

TREISER SL, CASCIO CS, O'DONOHUE TL, THOA NB, JACOBOWITZ DM, KELLAR KJ: Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. *Science* 1981; 213: 1529-1531

VATAL M, Aiyar AS: Some aspects of corticosterone metabolism in lithium treated rats. *Chem. Biol. Interactions* 1983; 45: 277-282

VON BARDELEBEN U, HOLSBOER F, STALLA GK, MÜLLER OA: Combined administration of human corticotropin-releasing factor and vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. *Life Sci* 1985; 37: 1613-1618

VON BARDELEBEN U, HOLSBOER F: Cortisol response to a combined dexamethasone-human corticotropin-releasing-hormone challenge in patients with depression. *Journal of Neuroendocrinology* 1989; 1: 485-488

VON BARDELEBEN U, HOLSBOER F: Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone. *Biol Psychiatry* 1991; 29: 1042-1050

WATSON S, YOUNG AH: The place of lithium salts in psychiatric practice 50 years on. *Curr Opin Psychiatry* 2001; 14: 57-63

WHITNALL MH: Regulation of the hypothalamic corticotropin-releasing hormone neurosecretory system. *Prog Neurobiol* 1993; 40: 573-629

WITTCHEN HU, WUNDERLICH U, GRUSCHWITZ S, ZAUDIG M: SKID-I. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Göttingen, Bern, Toronto, Seattle 1997, Hogrefe

WOLKOWITZ OM, REUS VI, MANFREDI F, INGBAR J, BRIZENDINE L, WEINGARTNER H: Ketokonazole administration in hypercortisolemic depression. *Am J Psychiat* 1993; 150: 810-812

ZATZ M, REISINE TD: Lithium induces corticotropin secretion and desensitization in cultured anterior pituitary cells. *Proc Natl Acad Sci USA* 1985; 82: 1286-1290

ZOBEL A, YASSOURIDIS A: Hormonal response to a combined dexamethasone/corticotropin-releasing hormone (DEX/CRH) test at remission predicts medium-term outcome in depression. *Pharmacopsychiatry* 1997; 30: 238

ZOBEL AW, YASSOURIDIS A, FRIEBOES RM, HOLSBOER F: Prediction of medium-term outcome by cortisol response to the combined dexamethasone/CRH-test in patients with remitted depression. *American Journal of Psychiatry* 1999; 156: 949-951

ZOBEL A, NICKEL T, SONNTAG A, UHR M, HOLSBOER F, ISING M: Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. *Journal of Psychiatric Research* 2001; 35: 83-94

ZUSKY PM, BIEDERMANN J, ROSENBAUM JF, MANSCHRECK TC, GROSS CC, WEILBERG JB, GASTFRIEND DR: Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. *J Clin Psychopharmacol* 1988; 8:120-124